{"entity":{"id":"oncodesign-precision-medicine","kind":"company","name":"Oncodesign Precision Medicine","aka":["OPM"],"tldr":"Oncodesign Precision Medicine is a small French company developing kinase-blocking medicines. Its OPM-101 is being prepared for a trial with pembrolizumab in advanced melanoma that no longer responds to immunotherapy.","summary":"Oncodesign Precision Medicine (OPM; ISIN FR001400CM63, ticker ALOPM), based in Dijon, was founded in 2022, according to the company, and specialises in precision medicine for resistant and metastatic cancers; it was co-founded by Philippe Genne, Jan Hoflack and Karine Lignel and employs 14 people. Its two clinical kinase inhibitors come from the Nanocyclix platform of macrocyclic kinase inhibitors: OPM-101, studied in healthy volunteers and now intended for immuno-oncology and chronic inflammatory bowel disease, and OPM-201, a Parkinson's disease programme funded by the Michael J. Fox Foundation. The REVERT phase 1b/2a protocol of OPM-101 with pembrolizumab in advanced melanoma resistant to anti-PD-1 was approved by Swiss regulatory and ethics authorities in late 2025 and was still in preparation in October 2026 (NCT07040436). The company reported a cash position of EUR 2.86 million at 30 June 2026. Its first registered interventional cancer trial, NCT07040436, was posted on ClinicalTrials.gov in June 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.oncodesign.com/"},{"label":"2026 half-year results release (PDF)","url":"https://www.oncodesign.com/wp-content/uploads/2026/10/PR_OPM_HYR-26_EN_22102026.pdf"},{"label":"ClinicalTrials.gov: REVERT phase 1b/2a trial of OPM-101 (NCT07040436)","url":"https://clinicaltrials.gov/study/NCT07040436"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year, ticker, HQ and trial status from the October 2026 half-year results release, read on 29 October 2026.","The molecular target of OPM-101 is not stated in the material read, so no target is linked.","An earlier observational study (OncoSNIPE, NCT04548960, posted 2020) was sponsored by the former parent Oncodesign SA, not by OPM.","The release states the accounts were prepared on a going concern basis with details to follow in the half-year report; that report was not read."],"hq":"Dijon","country":"FR","companyType":"biotech","website":"https://www.oncodesign.com/","ticker":"ALOPM","founded":2022,"stage":"public","investors":[],"funding":[]},"route":"/companies/oncodesign-precision-medicine/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}]}}